Phenotypic screening in the 21st century by Birgit T. Priest & Gul Erdemli
EDITORIAL
published: 01 December 2014
doi: 10.3389/fphar.2014.00264
Phenotypic screening in the 21st century
Birgit T. Priest1 and Gul Erdemli2*
1 Eli Lilly & Co., Indianapolis, IN, USA
2 Novartis, Cambridge, MA, USA
*Correspondence: gul.erdemli@novartis.com
Edited and reviewed by:
Salvatore Salomone, Catania University, Italy
Keywords: drug discovery, systems biology, label-free detection, phenotypic screening, gene networks
Since the advent of molecular cloning, target based screening
has become the norm in pharmaceutical drug discovery. A large
number of potential drug targets have been cloned and func-
tionally expressed, and enormous progress has been made in the
development, miniaturization and automation of cell based assays
on target molecules recombinantly expressed in mammalian cell
lines. This approach has delivered many clinical candidates but
relatively few new drugs. Target based screening is likely to pro-
vide very good drug candidates for monogenic diseases, and the
following collection ofmanuscripts is notmeant to discourage the
use of target based approaches. However, most of the more preva-
lent human diseases are most likely multifactorial and require
interaction with multiple targets to produce clinically meaning-
ful efficacy. In addition, high potency, selective interaction with a
single target may increases the risk of adverse events or be limited
by redundancies and adaptive resistance. Here, target agnostic
approaches using phenotypic assays may offer significant bene-
fit. Making such approaches viable requires addressing a number
of challenges. This e-book attempts to discuss some of these
challenges and illustrate recent advances.
Prior to the 1980s, most drugs were discovered using pheno-
typic assays in live animals or isolated tissues (Swinney, 2013).
Most of these drugs interact relatively weakly with a number
of targets, and the complete profile of their molecular interac-
tions is not well-known. Examples includemost anti-convulsants,
diuretics, and vasodilators. Screening in vivo typically returns
compounds with acceptable ADME properties and access to the
target in vivo; issues that often frustrate the present target based
drug discovery programs.
Screening in vivo may be feasible, if a good starting point
for Medicinal Chemistry and a clear strategy for differentiation
exist. An example is the development of carbamazepine analogs
with improved ADME properties (Landmark and Johannessen,
2008). In oncology, mouse xenograft models, based on a patient’s
tumor cells, have been used to select between drugs (Wu et al.,
2012). However, many drug discovery efforts rely on screening
to identify starting points for Medicinal Chemistry, and screen-
ing in vivo in most cases is not commercially or ethically viable.
In this case, phenotypic screening relies on an appropriate tissue-
or cell-based assay that can be miniaturized and used in combi-
nation with high throughput tools. Promising examples include
anti-microbial assays, cell proliferation, platelet aggregation, and
insulin release from pancreatic β-cells. For CNS diseases involv-
ing neuronal networks, selection of an appropriate substrate is
especially difficult. The article by Bruni et al. discusses the poten-
tial for using zebrafish as a model system, enabling large scale
behavior based screens for central nervous system disorders.
However, as pointed out by Bruni et al. there are substantial dif-
ferences in zebrafish and human biology and translation from
zebrafish to human may be problematic. In order to limit the
reliance on non-predictive animal models, screening strategies
utilizing human pluripotent stem cells (hPSCs) are increasingly
considered as resources for drug discovery. However, several hur-
dles need to be overcome before widespread implementation
of hPSC-based assays. Viswanathan and colleagues reviewed the
recent progress in the culture of hPSCs with emphasis on the
importance of the environment surrounding these cells and high
content analysis approaches for assay development.
The limited throughput of phenotypic assays compared to
most target-based assays necessitates smaller libraries that are
optimized with regard to biological and chemical diversity.
Wassermann and colleagues discuss strategies for building appro-
priate, well-annotated compound libraries. Such libraries may
also be used to identify pathways underlying the observed
effects.
Another challenge involves the identification of a phenotypic
end point associated with the disease of interest. In the early
phases of drug discovery, phenotypic assays can be used to further
our knowledge of the disease process and to identify those end
points that are most likely to translate to the clinic. Furthermore,
probability of success is greatly increased, if the end point mea-
sured can serve as a clinical biomarker. The perspective by Dr.
Swinney analyzes the phenotypic end points used in the discov-
ery of new molecular entities that have resulted from phenotypic
drug discovery efforts.
An additional hurdle to translation is the large genetic diver-
sity in the human population and the need to identify the right
patient population for any given drug. Progress has been made in
this regard in oncology. Ross et al. outline the approach taken for
cancer and the potential application to other diseases. Similarly,
the manuscript by Dr Schadt and colleagues points to the impor-
tance of gene networks for complex trait diseases and highlights
the importance of understanding these networks in the appropri-
ate biological context. In this regard, the integration of panomic
data will be increasingly important.
Label-free technologies can offer advantages for phenotypic
screening in that they do not involve assumptions about molec-
ular mechanisms and pathways. The manuscript by Dr. Fang
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reviews the use of label-free technologies with a focus onDynamic
Mass Redistribution (DMR). Many label-free technologies offer
the potential to be used as live cell kinetic assays. As discussed
by Dawson and Carragher, this is especially important for study-
ing drug combinations, since clinically successful combinations
require compatible pharmacokinetics of the individual com-
ponents. High content imaging is an attractive technology in
this regard, especially since it is compatible with organotypic
co-cultures. High content imaging can be combined with pro-
teomics to identify pathways and biomarkers, and Dawson and
Carragher describe some of the advances to increase throughput
of proteomics.
We would like to thank the authors for their outstanding con-
tributions and willingness to share their knowledge which made
this Special Topic possible. All the manuscripts have been peer-
reviewed and we are grateful to the expert reviewers for their
valuable comments.
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